Author:
Wang Geng,Tai Risheng,Wu Yanshuang,Yang Shanru,Wang Jingjing,Yu Xiaolan,Lei Lei,Shan Zhiyan,Li Na
Funder
National Nature Science Foundation of China
Heilongjiang Provincial Postdoctoral Science Foundation
University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province
China Postdoctoral Science Foundation
Heilongjiang Provincial Health and Family Planning Commission Foundation
Fund Program of Heilongjiang Province
Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Endocrinology, Diabetes and Metabolism
Reference172 articles.
1. Pembrolizumab: first global approval;Poole;Drugs,2014
2. Keytruda (Pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma;Raedler;Am. Health Drug Benefits,2015
3. Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma;Raedler;Am. Health Drug Benefits,2015
4. Nivolumab plus ipilimumab in advanced melanoma;Wolchok;N. Engl. J. Med.,2013
5. Cemiplimab: first global approval;Markham;Drugs,2018
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献